These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21411412)

  • 1. Multiple paradoxical adverse events in a patient affected with ankylosing spondylitis treated with TNF blockers.
    Lo Nigro A; Ramonda R; Alaibac M; Modesti V; Punzi L
    Eur J Dermatol; 2011; 21(2):263-4. PubMed ID: 21411412
    [No Abstract]   [Full Text] [Related]  

  • 2. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
    Famenini S; Wu JJ
    J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract]   [Full Text] [Related]  

  • 5. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
    Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
    Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
    [No Abstract]   [Full Text] [Related]  

  • 6. Onset of psoriasis during treatment with TNF-{alpha} antagonists: a report of 3 cases.
    Ubriani R; Van Voorhees AS
    Arch Dermatol; 2007 Feb; 143(2):270-2. PubMed ID: 17310016
    [No Abstract]   [Full Text] [Related]  

  • 7. Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists?
    Hernández MV; Ruiz-Esquide V; Gómez-Caballero ME; Gómez-Puerta JA; Cañete JD; Sanmartí R
    Rheumatology (Oxford); 2011 Aug; 50(8):1523-5. PubMed ID: 21593064
    [No Abstract]   [Full Text] [Related]  

  • 8. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.
    Sfikakis PP; Iliopoulos A; Elezoglou A; Kittas C; Stratigos A
    Arthritis Rheum; 2005 Aug; 52(8):2513-8. PubMed ID: 16052599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.
    Capkin E; Karkucak M; Yayli S; Aydin Çapkin A; Tosun M
    J Clin Rheumatol; 2011 Aug; 17(5):293-4. PubMed ID: 21808187
    [No Abstract]   [Full Text] [Related]  

  • 10. New-onset psoriasis associated with etanercept therapy.
    Chen LA; Su LH; Chang YJ; Hsu YL; Tsai TH
    J Dermatol; 2010 Apr; 37(4):378-80. PubMed ID: 20507411
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
    Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
    [No Abstract]   [Full Text] [Related]  

  • 12. Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.
    Modesti V; Ramonda R; Ortolan A; Lorenzin M; Lo Nigro A; Frallonardo P; Oliviero F; Campana C; Punzi L
    Scand J Rheumatol; 2012; 41(6):490-1. PubMed ID: 22985209
    [No Abstract]   [Full Text] [Related]  

  • 13. Do TNF-blockers reduce or induce uveitis?
    Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
    Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
    [No Abstract]   [Full Text] [Related]  

  • 14. [Biological treatment of ankylosing spondylitis].
    Freiesleben S; Schou M
    Ugeskr Laeger; 2008 Jun; 170(24):2140-5. PubMed ID: 18565298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists.
    Kary S; Worm M; Audring H; Huscher D; Renelt M; Sörensen H; Ständer E; Maass U; Lee H; Sterry W; Burmester GR
    Ann Rheum Dis; 2006 Mar; 65(3):405-7. PubMed ID: 16150791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
    Berg PA
    Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
    [No Abstract]   [Full Text] [Related]  

  • 17. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
    Pfueller CF; Seipelt E; Zipp F; Paul F
    Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of spondyloarthritides with anti-TNFalpha biologic agents.
    Braun J
    Reumatismo; 2006; 58 Spec No.1():71-2. PubMed ID: 23631067
    [No Abstract]   [Full Text] [Related]  

  • 19. Sensorineural hearing loss in ankylosing spondylitis treated with TNF blockers.
    Savastano M; Marioni G; Giacomelli L; Ramonda R; Ferraro SM; Punzi L
    B-ENT; 2010; 6(3):183-8. PubMed ID: 21090160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
    Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.